NCT04904302 2026-03-16
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
5 trialsNCT03015740 2024-11-19
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04518046 2024-06-05
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Mirati Therapeutics Inc.
Phase 1 Completed
NCT03606174 2023-08-24
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT02219711 2023-03-06
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Mirati Therapeutics Inc.
Phase 1 Completed